Free tool
FAERS Monitor: Nitrostat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021134 or its brand name (Nitrostat, Nitroglycerin). Reports on generic versions are filed under their own applications.
Reports
50,659
Serious
39,953
79% of reports
Hospitalization
22,965
Death reported
6,683
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea4,097
- pain3,585
- fatigue3,446
- myocardial infarction3,238
- nausea3,200
- drug ineffective2,960
- dizziness2,873
- chest pain2,869
- fall2,869
- diarrhoea2,649
- headache2,556
- renal failure2,467
- death2,379
- asthenia2,349
- hypotension2,219
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,000 |
| 2005 | 1,168 |
| 2006 | 999 |
| 2007 | 738 |
| 2008 | 946 |
| 2009 | 1,304 |
| 2010 | 1,528 |
| 2011 | 2,468 |
| 2012 | 2,114 |
| 2013 | 1,251 |
| 2014 | 3,042 |
| 2015 | 2,372 |
| 2016 | 2,914 |
| 2017 | 2,764 |
| 2018 | 3,081 |
| 2019 | 3,145 |
| 2020 | 2,768 |
| 2021 | 2,666 |
| 2022 | 3,197 |
| 2023 | 3,162 |
| 2024 | 3,072 |
| 2025 | 2,988 |
| 2026 | 1,968 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,500 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal failureSignal | 2,467 | 7.8 | 7.5 | 14,534 |
| myocardial infarctionSignal | 3,238 | 7.8 | 7.6 | 19,092 |
| chest painSignal | 2,869 | 6.5 | 6.3 | 13,303 |
| hypotensionSignal | 2,219 | 4.6 | 4.4 | 6,308 |
| fallSignal | 2,869 | 3.6 | 3.5 | 5,428 |
| dyspnoeaSignal | 4,097 | 3.0 | 2.9 | 5,643 |
| astheniaSignal | 2,349 | 2.6 | 2.5 | 2,346 |
| painSignal | 3,585 | 2.4 | 2.4 | 3,092 |
| dizzinessSignal | 2,873 | 2.4 | 2.3 | 2,387 |
| fatigue | 3,446 | 1.8 | 1.8 | 1,369 |
| diarrhoea | 2,649 | 1.7 | 1.6 | 796 |
| headache | 2,556 | 1.7 | 1.6 | 748 |
| nausea | 3,200 | 1.7 | 1.6 | 914 |
| death | 2,379 | 1.1 | 1.1 | 46 |
| drug ineffective | 2,960 | 0.9 | 0.9 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.